Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMEDIATE early IVIg pilot study in newly diagnosed idiopathic inflammatory myopathies
NL-OMON25293Active, not recruiting
- Sponsor
- Amsterdam UMC, Department of Neurology
- Start
- Jan 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in Autoimmune Myopathies, dermatomyositis (DM), polymyositis (PM) and 3 more, sponsored by Amsterdam UMC, Department of Neurology. Primary endpoint: Clinically significant improvement at 9 weeks. Started Jan 2017; status: active, not recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)Overlap Myositis (OM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on NL-OMON25293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25293.